Suppr超能文献

碘化钾对格雷夫斯病甲状腺切除术的影响:对安全性和手术难度的启示

Impact of potassium iodide on thyroidectomy for Graves' disease: Implications for safety and operative difficulty.

作者信息

Randle Reese W, Bates Maria F, Long Kristin L, Pitt Susan C, Schneider David F, Sippel Rebecca S

机构信息

Department of Surgery, University of Wisconsin, Madison, WI.

Department of Surgery, University of Wisconsin, Madison, WI.

出版信息

Surgery. 2018 Jan;163(1):68-72. doi: 10.1016/j.surg.2017.03.030. Epub 2017 Nov 3.

Abstract

BACKGROUND

Potassium iodide often is prescribed prior to thyroidectomy for Graves' disease, but the effect of potassium iodide on the ease and safety of thyroidectomy for Graves' is largely unknown.

METHODS

We conducted a prospective, cohort study of patients with Graves' disease undergoing thyroidectomy. For the first 8 months, no patients received potassium iodide; for the next 8 months, potassium iodide was added to the preoperative protocol for all patients. Outcomes included operative difficulty (based on the Thyroidectomy Difficulty Scale) and complications.

RESULTS

We included a total of 31 patients in the no potassium iodide group and 28 in the potassium iodide group. According to the Thyroidectomy Difficulty Scale, gland vascularity decreased in the potassium iodide group (mean score 2.6 vs 3.3, P = .04), but there were no differences in friability, fibrosis, or size of the thyroid or in overall difficulty of operation (P = not significant for all). Despite similar operative difficulty, patients prescribed potassium iodide were less likely to experience transient hypoparathyroidism (7% vs 26%, P = .018) and transient hoarseness (0% vs 16%, P = .009) compared with the no potassium iodide group.

CONCLUSION

Potassium iodide administration decreases gland vascularity, but does not change the overall difficulty of thyroidectomy. Preoperative use of potassium iodide solution was, however, associated with less transient hypoparathyroidism and transient hoarseness, suggesting that potassium iodide improves the safety of thyroidectomy for Graves' disease.

摘要

背景

对于格雷夫斯病患者,甲状腺切除术前常开具碘化钾,但碘化钾对格雷夫斯病甲状腺切除术的操作便利性和安全性的影响很大程度上尚不清楚。

方法

我们对接受甲状腺切除术的格雷夫斯病患者进行了一项前瞻性队列研究。在最初的8个月里,没有患者接受碘化钾;在接下来的8个月里,所有患者的术前方案中都添加了碘化钾。结果包括手术难度(基于甲状腺切除难度量表)和并发症。

结果

碘化钾未治疗组共纳入31例患者,碘化钾治疗组共纳入28例患者。根据甲状腺切除难度量表,碘化钾组腺体血管化程度降低(平均评分2.6对3.3,P = 0.04),但在甲状腺的脆性、纤维化程度或大小以及总体手术难度方面没有差异(所有P值均无统计学意义)。尽管手术难度相似,但与未使用碘化钾组相比,服用碘化钾的患者发生短暂性甲状旁腺功能减退的可能性较小(7%对26%,P = 0.018),发生短暂性声音嘶哑的可能性也较小(0%对16%,P = 0.009)。

结论

服用碘化钾可降低腺体血管化程度,但不会改变甲状腺切除术的总体难度。然而,术前使用碘化钾溶液与较少的短暂性甲状旁腺功能减退和短暂性声音嘶哑相关,这表明碘化钾可提高格雷夫斯病甲状腺切除术的安全性。

相似文献

引用本文的文献

3
Preoperative preparation for Graves' disease.格雷夫斯病的术前准备。
Front Endocrinol (Lausanne). 2023 Aug 23;14:1234056. doi: 10.3389/fendo.2023.1234056. eCollection 2023.
6
Hyperthyroidism.甲状腺功能亢进症
Gland Surg. 2020 Feb;9(1):124-135. doi: 10.21037/gs.2019.11.01.

本文引用的文献

4
Management of Graves Disease: A Review.格雷夫斯病的治疗:综述。
JAMA. 2015 Dec 15;314(23):2544-54. doi: 10.1001/jama.2015.16535.
5
Thyroid surgery for Graves' disease and Graves' ophthalmopathy.用于治疗格雷夫斯病和格雷夫斯眼病的甲状腺手术。
Cochrane Database Syst Rev. 2015 Nov 25;2015(11):CD010576. doi: 10.1002/14651858.CD010576.pub2.
8
Identifying predictors of a difficult thyroidectomy.确定甲状腺切除术困难的预测因素。
J Surg Res. 2014 Jul;190(1):157-63. doi: 10.1016/j.jss.2014.03.034. Epub 2014 Mar 19.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验